Vancouver, BC (January 3, 2023) – WEX Pharmaceuticals Inc. (“WEX” or the “Company”), a biotechnology company developing Halneuron® (Tetrodotoxin or TTX) for pain, announced that the first patient has been dosed in its Phase 2B clinical trial evaluating the efficacy and safety of Tetrodotoxin in the treatment of Chemotherapy-Induced Neuro…